Hile Bio-Technology cuts acquisition price for Shaanxi Ruisheng equity

Shanghai Hile Bio-Technology has adjusted the transaction price for its acquisition of 55% equity in Shaanxi Ruisheng Bio-Technology. Initially set at 935 million yuan, the price has been revised to 535.7 million yuan, following a re-evaluation of Shaanxi Ruisheng's equity value at 974 million yuan, down from the previous 1.7 billion yuan. This adjustment results in a refund of 399.3 million yuan from Meilun Management Co.

The adjustment stems from a "price war" in the dental restorative materials market due to increased competition and stricter enforcement of tax policies, which impacted Shaanxi Ruisheng’s profitability. Net profit commitments for 2025 and 2026 have also been adjusted to 50 million yuan and 58 million yuan, respectively. The changes were approved by the company's board, independent directors, and audit committee, and are subject to shareholder approval. The company will retain 55% ownership of Shaanxi Ruisheng.